Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Sponsor
Bristol-Myers Squibb
Study ID
NCT00357461
Phase
PHASE2
Status
Withdrawn

Conditions

  • Melanoma (Skin)

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • gp100:209-217(210M) peptide vaccine — BIOLOGICAL
  • gp100:280-288(288V) peptide vaccine — BIOLOGICAL
  • incomplete Freund's adjuvant — BIOLOGICAL
  • ipilimumab — BIOLOGICAL

Study Details

RATIONALE: Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Vaccines made from gp100 peptides may help the body build an effective immune response to kill tumor cells. Giving ipilimumab together with vaccine therapy may be an effective treatment for melanoma. PURPOSE: This randomized phase II trial is studying ipilimumab and vaccine therapy to see how well they work compared to ipilimumab alone in treating patients with previously treated stage IV melanoma.

Key Dates

Start date
May 31, 2006
Status verified
May 2013

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Primary purpose
TREATMENT

Primary Outcome Measure

Clinical response

Related Studies